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Isolation of Heptadepsin,
a Novel Bacterial Cyclic Depsipeptide
that Inhibits Lipopolysaccharide Activity
circulating cells into the endothelium plays an important
role more generally at sites of inflammation [3]. Under
normal circumstances, blood leukocytes do not adhere
to the endothelium. However, under inflammatory condi-
tions, exogenous stimuli such as bacterial lipopolysac-
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Tokyo 108-8639 like receptor (TLR) 4 on the cell surface of monocytes,
macrophages, neutrophils, and endothelial cells inJapan
mammals [5]. Especially in endothelial cells, LPS in-
duces (1) production of proinflammatory cytokines such
as IL-6 [6], IL-8 [7], and IL-1 [8], (2) upregulation ofSummary
adhesion molecules such as intercellular adhesion mol-
ecule-1 (ICAM-1), vascular cell adhesion molecule-1Lipopolysaccharide (LPS) is considered to cause vari-
(VCAM-1), and E-selectin [9], and (3) expression of tissueous inflammatory reactions. We searched among mi-
factor [10]. TLR4 was identified as the putative trans-crobial secondary metabolites for compounds that
membrane receptor for LPS that activates nuclear fac-could inhibit LPS-stimulated adhesion between hu-
tor-B (NF-B) signaling [11–13]. NF-B is known to playman umbilical vein endothelial cells (HUVEC) and hu-
a critical role in the development of the inflammatoryman myelocytic cell line HL-60 cells. In the course of
response by upregulating the expression of many in-our screening, we isolated a novel cyclic depsipeptide,
flammatory cytokines and cell adhesion molecules.which we named heptadepsin, from the whole culture
The recruitment of leukocytes into the inflamed endo-broth of Paenibacillus sp. The addition of heptadepsin
thelium involves inflammatory stimulus-induced expres-prior to LPS stimulation decreased HL-60 cell-HUVEC
sion of multiple cell adhesion molecules on the surfaceadhesion without showing any cytotoxicity. It also in-
of endothelial cells. The most important of these mole-hibited the cellular adhesion induced by lipid A, the
cules involved in this process are ICAM-1, VCAM-1, andactive component of LPS, but it did not inhibit TNF-
E-selectin [4, 9]. Only a small amount of ICAM-1 is pres-or IL-1-induced cell adhesion. The result of surface
ent on the endothelium without stimulation [14], andplasmon resonance (SPR) analysis revealed that hep-
VCAM-1 and E-selectin are absent entirely [15, 16]. How-tadepsin interacted with lipid A directly. Thus, hepta-
ever, they are immediately expressed in response todepsin, a novel naturally occurring cyclic heptadepsi-
extracellular inflammatory stimulation [17]. Each stimu-peptide, was shown to inactivate LPS by direct
lus induces its selective expression of these adhesioninteraction with LPS.
molecules, whose expression may contribute to the se-
lective recruitment of leukocyte subtypes specific to
Introduction the endothelial cells at sites of inflammation. ICAM-1
interacts with the ligand CD11a/CD18 (LFA-1), which is
The vascular endothelium is intimately involved in a wide expressed on neutrophils, lymphocytes, and mono-
variety of physiological processes, including coagula- cytes, and VCAM-1 interacts with the ligand VLA-4,
tion/anticoagulation, maintenance of the vascular tone, which is expressed on lymphocytes. E-selectin medi-
and immune reactions. However, it is also involved in ates the adherence of neutrophils, T cells, eosinophils,
various pathological processes, including atherosclero- and monocytes.
sis, inflammation of other tissues, and blood-borne tu- As described above, LPS is implicated in the patho-
mor metastasis [1]. In the case of atherosclerosis, the genesis of gram-negative bacteria infections and its at-
pathogenesis involves a series of critical events includ- tendant vascular complications. Because it triggers an
ing endothelial dysfunction, infiltration of monocytes inflammation in bowels, including Crohn disease [18,
into the vessel wall, differentiation of monocytes, and 19] and periodontitis [20, 21], LPS is considered to be
vascular remodeling [2]. The first critical step is the re- one of the most common and potent pathogenic factor
cruitment of circulating monocytes into the inflamed of blood vessels. Therefore, searching for molecules
endothelium of the blood vessel. Recruitment of blood that can inhibit LPS-induced endothelial cell dysfunction




As microorganisms produce a variety of compounds Supplemental Table S2. They appeared similar to those
of fusaricidins produced by Bacillus polymyxa [26] orof low molecular weight having unique structures, they
are ideal sources of novel bioactive secondary metabo- circulocins produced by Bacillus circulans [27], but were
not identical. The multiplicities of carbon signals werelites. Thus, in the present study, we searched among
microbial secondary metabolites for compounds that determined by DEPT experiments, and all bond corre-
spondence between 1H and 13C signals was determinedcould inhibit the adhesion of human myelocytic cell line
HL-60 cells to LPS-stimulated human umbilical vein en- by DEPT and HMQC experiments. Detailed analysis of
2D 1H-1H COSY, HMQC, HMBC, and ROESY data fordothelial cells (HUVEC). As a result, we isolated a novel
cyclic depsipeptide named heptadepsin from the whole heptadepsin revealed the presence of 7 amino acids:
alanine 1 (Ala1), asparagine (Asn), serine 1 (Ser1), alanineculture broth of Paenibacillus sp. BML771-113F9. Our
data suggested that heptadepsin interacts with LPS di- 2 (Ala2), isoleucine (Ile), valine (Val), and serine 2 (Ser2).
As described in the Experimental Procedures, the chiral-rectly.
ity of these amino acids was determined by acid hydroly-
sis (6 N, 105C, 17 hr) of heptadepsin. This result indi-Results
cated the presence of D-Ala, D-Asn, L-Ser, L-Ile, and
D-Val. Ser1 and Ser2 were both L-Ser, and Ala1 andIsolation of Heptadepsin
Ala2 were both D-Ala, so the absolute stereochemistryWe constructed the screening system for low molecular
of them was the same. In addition, amino acid analysis ofweight compounds that inhibit the adhesion of HL-60
L-Ile by HPLC (column; Hitachi custom ion exchangingcells to LPS-stimulated HUVEC. We searched such com-
resin #2622) showed that it was not L-allo-Ile.pounds among several thousand samples from natural
The sequence of the 7 amino acids and GHHD residuesources, such as culture broths of Streptomyces, bacte-
in heptadepsin was determined on the basis of 1H-13Cria, and plant extracts. We took into account only the
HMBC data shown in Figure 1B. The respective two-samples without cytotoxicity. The hitting rate was less
bond correlations from amide NHs of Val, Ile, Ala1, Ser2,than 1/1000. In the course of our screening, the filtrate
Asn and Ala2 to C-1 carbonyls of Ser1, Val, Ile, Ala1,from Paenibacillus sp. BML771-113F9 revealed marked
Ser2, and Asn allowed the sequence to be establishedinhibitory activity toward HL-60 cell adhesion to LPS-
as Ser1-Val-Ile-Ala1-Ser2-Asn-Ala2. The three-bondstimulated HUVEC. From the whole culture broth of Pae-
correlation between H-3 (Ser1) and C-1 (Ala2) acrossnibacillus sp. BML771-113F9, the active principle was
the ester linkage was also observed by changing theisolated through the several chromatographic separa-
measurement condition of the PI1 value from 60 to 120tions described in the Experimental Procedures. Spec-
ms, which established the cyclic heptadepsipeptidetroscopic analysis of the active compound revealed that
system.the compound was a novel cyclic heptadepsipeptide,
A long chain acid terminating in a guanidino groupand so we named it heptadepsin (Figure 1A). Related
was suggested to have a linear chain of 14 methylenesknown naturally occurring cyclic heptadepsipeptides in-
between the -hydroxy and the guanidino groups onclude HUN-7293, which inhibits inducible cell-adhesion
the basis of NMR spectra as shown in Supplementalmolecule expression as does heptadepsin [22]. How-
Table S2 and Figure 1. Additional support for this frag-ever, the amino acid composition of HUN-7293 is much
ment was obtained by FAB-MS analysis and by the colordifferent from that of heptadepsin, containing Leu and
reaction of an EtOAc extract of an acid hydrolysate (6 N,unusual tryptophan and leucines [23].
105C, 17 hr) of heptadepsin with the Sakaguchi reagent.
The FAB-MS spectrum of the acid hydrolysate con-
Physico-Chemical Properties tained a prominent ion at m/z 344, corresponding to the
Heptadepsin was obtained as a white amorphous pow- (MH) for 17-guanidino-3-hydroxyheptadecanoic acid
der, and its physico-chemical properties are summa- (GHHD). In addition, the acid hydrolysate gave a positive
rized in Supplemental Table S1. It was easily soluble in reaction with the Sakaguchi reagent. Thus, this long
MeOH and DMSO, slightly soluble in water, and insolu- chain acid was concluded to have a guanidino group.
ble in CHCl3, EtOAc, and n-hexane. It gave a positive The absolute configuration of C-3 of GHHD remains to
reaction with the Sakaguchi reagent [24, 25], but was be determined.
negative in the ninhydrin test. The color reactions and The attachment of GHHD to the amino group on Ser1
1H and 13C NMR data suggested that heptadepsin was was confirmed by the two-bond correlation between the
a cyclic depsipeptide having a guanidino group. The UV amide NH of Ser1 and C-1 of GHHD. Additional two- or
spectrum of heptadepsin showed absorption at 210 nm. three-bond correlations in the HMBC spectrum and ROE
The IR spectrum of heptadepsin exhibited typical ab- cross peaks in the ROESY spectrum supported the
sorption bands of amides at 1658, 1635, and 1539 cm1 structure of heptadepsin indicated in Figure 1.
and an ester at 1753 cm1. The molecular formula of
heptadepsin was determined to be C45H81N11O12 by
HRFAB-MS (pos.): m/z 968.6133 (M  H) (C45H82N11O12 Inhibition of Leukemic Cell Adesion
calculated mass 968.6144). to LPS-Stimulated HUVEC
When HUVEC were unstimulated or pretreated with
3 g/ml heptadepsin alone, no prominent HL-60 cellStructure Determination of Heptadepsin
The molecular formula of heptadepsin was determined adhesion was observed. Treatment of HUVEC with 1g/ml
LPS for 4 hr significantly increased the adhesion of HL-to be C45H81N11O12 from HRFAB-MS and NMR spectra.
The 1H and 13C NMR spectra of heptadepsin were mea- 60 cells. However, the addition of heptadepsin at 3g/ml
prior to LPS stimulation markedly decreased the HL-60sured in DMSO-d6, and those data are summarized in
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Figure 1. Structure Determination of Hepta-
depsin
(A) Structure of heptadepsin. (B) HMBC and
ROE correlations of heptadepsin.
cell-HUVEC adhesion (Figure 2A). The IC50 value was that heptadepsin inhibited 1g/ml LPS-induced expres-
sion of ICAM-1 and VCAM-1 at 3 g/ml almost com-determined to be 0.92 g/ml, as shown in Figure 2B.
Furthermore, incubation with 1 g/ml LPS for 4 hr in- pletely (Figure 2C). LPS did not induce E-selectin in our
preparation of HUVEC.creased the adhesion of human monocyte cell line
THP-1 cells or human T cell leukemia Jurkat cells, and
heptadepsin also inhibited these leukemic cell adhe- Heptadepsin Was Not Cytotoxic or Growth
Inhibitory toward HUVECsions to HUVEC (THP-1: IC50  1.29 g/ml; Jurkat: IC50 
1.57 g/ml; data not shown). Lipid A, the active compo- To exclude the possibility that heptadepsin inhibited
adhesion by its cytotoxicity to HUVEC, we examinednent of LPS, also induced the adhesion of HL-60 cells
to HUVEC, which was again inhibited by heptadepsin the cytotoxicity and growth inhibition by using a trypan
blue dye exclusion assay and MTT assay, respectively.(Figure 2B). Next, we employed stimulants other than
LPS, such as TNF- and IL-1. As shown in Figure 2B, Heptadepsin did not show any cytotoxicity after 24 hr
or growth inhibition after 72 hr toward HUVEC up to 3010 ng/ml TNF- or 10 ng/ml IL-1 induced the adhesion
of HL-60 cells to HUVEC; however, heptadepsin did not g/ml, with or without LPS (Figure 3).
inhibit these adhesions. Therefore, heptadepsin ap-
peared to act specifically on LPS or lipid A. Inhibition of Fluorescent-Conjugated LPS Binding
to TLR4-Overexpressing Ba/F3 CellsInhibition of leukemic cell adhesion to LPS-stimulated
HUVEC by heptadepsin might be expected to be due Then, we examined the effect of heptadepsin on the
binding of fluorescent-conjugated LPS to the cells over-to a decrease in LPS-induced adhesion molecule ex-
pression. So, we examined the effect of heptadepsin on expressing the LPS receptor, TLR4. We employed
mouse pro B Ba/F3 cells stably expressing mouse TLR4,LPS-induced expression of adhesion molecules such as
ICAM-1 and VCAM-1. Western blotting analysis revealed mouse MD-2, and mouse CD14. Fluorescence micro-
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Figure 2. Inhibition of HL-60 Cell Adhesion to
LPS-Stimulated HUVEC by Heptadepsin
(A) HUVEC were preincubated or not with
3 g/ml heptadepsin for 2 hr, treated or not
with LPS (1g/ml) for 4 hr, and, after washing,
incubated with HL-60 cells for 1 hr.
(B) HUVEC were preincubated with the indi-
cated concentrations of heptadepsin for 2 hr
and then treated (solid columns) or not (open
columns) with 1 g/ml LPS, 1 g/ml lipid A,
10 ng/ml TNF-, or 10 ng/ml IL-1 for 4 hr.
After washing, HL-60 cells were added to the
HUVEC. One hour later, the adhesion of HL-
60 cells to HUVEC was determined by mea-
suring the number of adherent cells in 1 mi-
croscopic field. Values are the means 	 SD
of triplicate determinations.
(C) Adhesion molecule expression in LPS-
activated HUVEC was inhibited by heptadep-
sin. HUVEC were treated with the indicated
concentrations of heptadepsin for 2 hr and
then stimulated or not with 1g/ml LPS for 4 hr.
The cell lysates were analyzed by Western
blotting with anti-ICAM-1 and anti-VCAM-1
antibodies.
scopic analysis revealed the binding of Alexa-LPS to firmed that heptadepsin did not interact with the fluores-
cence of Alexa Fluor 488 by in vitro analysis using athe Ba/F3 transformants, and addition of heptadepsin
prior to Alexa-LPS markedly decreased the binding of fluorescence spectrophotometer (data not shown). Fur-
thermore, heptadepsin did not decrease the viability ofAlexa-LPS to the cells in a dose-dependent manner (Fig-
ure 4A). An excess amount of nonlabeled LPS (cold LPS) Ba/F3 transformants up to 3 g/ml, with or without LPS
at 24 hr treatment (data not shown). Thus, heptadepsinalso decreased the fluorescence. FACS analysis of the
binding of Alexa-LPS to the cell surface receptor gave was demonstrated to block the binding of LPS to the
cell surface overexpressing TLR4.the similar results, as shown in Figure 4B. It was con-
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Figure 3. Effects of Heptadepsin on Viability
and Growth of HUVEC
(A) HUVEC were treated with the indicated
concentrations of heptadepsin for 24 hr in
the absence (open circles) or presence (solid
circles) of 1 g/ml LPS, and cell viability was
determined by trypan blue dye exclusion. Val-
ues are the means 	 SD of quadruplicate
determinations.
(B) HUVEC were treated with the indicated
concentrations of heptadepsin for 72 hr in
the absence (open circles) or presence (solid
circles) of 1 g/ml LPS, and the cell number
was determined by using the MTT assay. Val-
ues are the means	 SD of triplicate determi-
nations.
Effect of Heptadepsin on Taxol-Induced NF-B ity of LPS. To examine this possibility, we looked into
the real-time interaction between heptadepsin and lipidActivation in Ba/F3 Cells
Taxol, an antitumor agent derived from a plant, was A by using surface plasmon resonance (SPR) analysis.
A strong binding signal was observed when heptaepsinreported to mimic the action of LPS in mice [28, 29].
TLR4 and MD-2 were demonstrated to be necessary for was applied to immobilized lipid A on the HPA sensor
chip (Figure 6A). The rapid increase of resonance unitthe response to taxol [30–32]. Thus, both taxol and LPS
require the TLR4-MD-2 complex for their signal trans- (RU) by binding of heptadepsin to lipid A indicated the
duction. To study whether heptadepsin acts on the LPS associated changes in mass during the reaction, dem-
receptor, we examined the effect of heptadepsin on onstrating the direct interaction between heptadepsin
taxol-induced activation of NF-B, the downstream sig- and lipid A. Because time-dependent dissociation was
naling of TLR4. As a result, although heptadepsin inhib- observed, the type of interaction between heptadepsin
ited LPS-induced NF-B activation in Ba/F3 cells (Figure and lipid A is likely to be reversible. Polymyxin B, known
5A), it did not inhibit taxol-induced NF-B activation to bind to lipid A, induced the resonance in our SPR
(Figure 5B). These results suggested that heptadepsin analysis, but ring-opened heptadepsin that was inactive
did not interact with LPS receptors. to inhibit HL-60/HUVEC adhesion did not (data not
shown). We also calculated the kinetic parameters such
as ka, kd, and KD using BIAcore evaluation software ver-Analysis of the Direct Interaction
sion 3.0. The dissociation rate (kd), the association ratebetween Heptadepsin and LPS
(ka), and the apparent dissociation constant (KD) of hep-Since heptadepsin did not inhibit TNF-, IL-1, or taxol-
tadepsin binding to lipid A were calculated to be 2.04 
induced signaling, it is likely that heptadepsin directly
acts on LPS, especially on lipid A, to inactivate the activ- 103 s1, 10.4 M1 s1, and 1.97 
 104 M, respectively.
Figure 4. Inhibition of Fluorescent LPS Bind-
ing to Ba/F3 Cells Expressing TLR4-MD-2
and CD14 by Heptadepsin
(A) Ba/F3 transformants were incubated with
the indicated concentrations of heptadepsin
or 10 g/ml cold LPS for 30 min. Then, the
cells were treated with 1 g/ml Alexa Fluor
488-conjugated LPS for 30 min. After wash-
ing, binding of Alexa-LPS to the cells was
analyzed by fluorescence (upper panel) and
phase contrast (lower panel) microscopy.
(B) FACS analysis for the binding of Alexa-
LPS to Ba/F3 transformants was carried out
after the cells were cultured as in (A). The
histograms represent the fluorescence of
Ba/F3 transformants treated with (bold line)
or without (dotted line) 1 g/ml Alexa-LPS in
the presence of the indicated concentrations
of heptadepsin or 10 g/ml cold LPS.
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Figure 5. Effect of Heptadepsin on Taxol-
Induced NF-B Activation in Ba/F3 Cells Ex-
pressing TLR4-MD-2 and CD14
Ba/F3 transformants were incubated with the
indicated concentrations of heptadepsin for
30 min. Then, the cells were treated with or
without 10 ng/ml LPS (A), or 1 g/ml taxol (B)
for 4 hr. The luciferase activity was measured
with a luminometer. Values are the means 	
SD of quadruplicate determinations.
These results showed that heptadepsin interacted with by Bacilli can be classified into two groups. The first
group has a common feature in that the N terminus oflipid A directly to inhibit the LPS activity.
the peptide chain is bound to the long chain acid via theWe also looked into the interaction between hepta-
amide bond, and the carboxyl group on the C terminusdepsin and LPS using heptadepsin absorpsion by LPS.
forms a lactone with the -hydroxy group, as seen inTo study whether LPS could inactivate heptadepsin, we
surfactin [36] and lichenysins [37], or forms a lactamemployed a large molecule-remaining filter and centrifu-
with the -amino group, as seen in iturins [38] and bacil-gation to remove LPS-bound heptadepsin (Figure 6B).
lomycins [39]. In these compounds, the long chain acidHeptadepsin and LPS were mixed and incubated in a
is incorporated into the ring system. The second groupcell-free condition for 1 hr at 37C, and then the mixed
includes fusaricidins [26], circulocins [27], pipastatinssolution was ultrafiltered in a centrifugal filter device. In
[40], colistins [41], and octapeptins [42], in which the Nthis procedure, molecules bound to LPS stayed in the
terminus of the cyclic peptide is bound to the long chainretentate with LPS. If heptadepsin bound to LPS, it
acid by the amide bond lying outside the ring system.would not pass through the filter membrane of the cen-
Heptadepsin belongs to the second group and containstrifugal filter device, and thus the filtrate should not show
a heptadepsipeptide core and a long chain acid with aany inhibitory activity toward cell adhesion. For the con-
terminal guanidino group. Although Bacilli producetrol experiments, we employed bovine serum albumin
many cyclic peptides, there has been no compound(BSA) and lipoteichoic acid (LTA). As a result, the hepta-
among them reported to inhibit LPS-induced cell adhe-depsin fraction that had been pretreated with LPS
sion. Actually, we tested the effect of fusaricidins A andshowed no inhibitory activity toward HL-60 cell adhesion
B, which also belong to the second group of the cyclicto LPS-stimulated HUVEC. On the other hand, hepta-
peptides, on the cell adhesion between HL-60 cells anddepsin pretreated with BSA or LTA maintained its inhibi-
LPS-stimulated HUVEC. However, they showed no in-tory activity (Figure 6C). Previously, we confirmed that
hibitory activity (data not shown).LPS itself did not pass through the filter membrane of
Our present study demonstrated that heptadepsinthe centrifugal filter device after ultrafiltration (data not
showed significant inhibitory activity against HL-60 cellshown). Moreover, the molecular weight of LPS was
adhesion to LPS-stimulated HUVEC (Figure 2) and thatpresumed to be over 3000 [33], which is the nominal
the inhibition occurred without toxicity or growth inhibi-molecular weight limit in daltons of the centrifugal filter
tion (Figure 3). This biological activity was proved to bedevice we used. In addition, the molecular weight of
caused by the inhibition of LPS-induced expression ofBSA is 68,000, and that of LTA used in this study is also
adhesion molecules ICAM-1 and VCAM-1 in HUVECover 3,000 [34], and so they could not pass through the
(Figure 2C). Until now, only the naturally occurring cyclicfilter membrane.
heptadepsipeptide HUN-7293, isolated from a fungalFrom these results, heptadepsin was concluded to
broth, had been reported to inhibit inducible cell-adhe-interact with LPS directly, as shown in Figure 7. Thus,
sion molecule expression [23]. HUN-7293 is structurallyheptadepsin appears to be a unique inhibitor of LPS
different from heptadepsin in the following two points:signal transduction, interacting with LPS itself.
its amino acid content and the absence of a long chain
acid lying outside the cyclic system. HUN-7293 inhibited
Discussion TNF--induced expression of ICAM-1 and VCAM-1 in
human microvascular cell line HMEC-1 [22]. Because
We looked among microbial secondary metabolites for heptadepsin did not inhibit the signal transduction of
compounds that could inhibit HL-60 cell adhesion to TNF- or IL-1 (Figure 2B), the mechanisms of the ac-
LPS-stimulated HUVEC. Among several thousand mi- tions of heptadepsin and HUN-7293 must be different.
crobial culture filtrates tested, we isolated a novel com- We found that heptadepsin blocked the binding of
pound, heptadepsin, from the culture broth of Paeni- fluorescent-conjugated LPS to its receptors by using
bacillus sp. BML771-113F9. Paenibacillus arose from Ba/F3/TLR4/MD-2/CD14 cells (Figure 4). In addition, we
strains of Bacillus reported to produce other bioactive revealed that heptadepsin directly interacted with lipid
A by the SPR analysis and in vitro adsorption assaycyclic peptides [35]. Bioactive cyclic peptides produced
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Figure 6. Interaction of Heptadepsin and LPS
(A) SPR analysis of the direct binding of heptadepsin and immobilized lipid A. Sensorgrams indicate the association and dissociation phases
of the reactions when heptadepsin (1, 3, 4, and 5 g/ml, from bottom to top) was injected for 2 min at 20 l/min over the monolayer of lipid
A immobilized on the HPA sensor chip.
(B) Procedure of the heptadepsin adsorption assay.
(C) Heptadepsin was mixed with LPS, BSA, or LTA for 1 hr, and then the mixture was ultrafiltered. The filtrate was then assayed for inhibitory
activity toward HL-60 cell adhesion to LPS-stimulated HUVEC. HUVEC were preincubated with the indicated theoretical concentrations of
heptadepsin pretreated with LPS, BSA, or LTA for 2 hr and then treated (solid columns) or not (open columns) with 1 g/ml LPS for 4 hr. After
the HUVEC had been washed, HL-60 cells were added. One hour later, the adhesion of HL-60 cells to HUVEC was determined by measuring
the number of adherent cells in 1 microscopic field. Values are the means 	 SD of triplicate determinations.
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Figure 7. Scheme of Signal Transduction on
Ligand-Induced Expression of Adhesion Mol-
ecules
using centrifugal filter devices (Figure 6). These results the binding of LPS to CD14-expressing cells [50, 53].
Because heptadepsin was shown to possess LPS-inter-strongly indicated that heptadepsin directly interacted
with LPS to block the downstream of LPS-TLR4 signal acting activity, the mechanism by which heptadepsin
blocks the biological activities of LPS may be similar totransduction. Until now, several naturally occurring
compounds, mostly peptides, were reported to inhibit that of the cathelicidin family.
In addition, neutralizing antibodies against LPS andLPS signal transduction by neutralizing LPS itself. One
such compound that possesses LPS-neutralizing activ- LPS binding protein (LBP) have been shown to suppress
the cascade of LPS-induced inflammatory reactionsity is polymyxin B [43]. Polymyxin B is a naturally oc-
curring cationic cyclic decapeptide isolated from Bacil- [54–56].
Newly discovered heptadepsin was found to be a se-lus polymyxa [44]. It consists of a positively charged
cyclic peptide ring and a long chain acid tail. The LPS- lective inhibitor of LPS signal transduction, interacting
with LPS itself. Recently, much attention has focusedneutralizing activity of polymyxin B is due to its high-
affinity binding to the highly conserved hydrophobic do- on the low molecular weight compounds that possess
LPS-neutralizing activities. Because the molecular weightmain of LPS, which is lipid A [45]. By the SPR analysis,
polymyxin B was indicated to possess the ability to bind of heptadepsin is lower than that of other known LPS-
neutralizing agents, and because of its minimal cytotox-to lipid A and LPS directly [46, 47]. Because polymyxins
were comparatively toxic antibiotics, the cyclic peptides icity, heptadepsin may have therapeutic potential for
the treatment of LPS-triggered syndromes. Thus, hepta-(nonapeptide) derived from polymyxin B were studied
for reducing the toxicity [48]. Although polymyxin B and depsin is an attractive candidate for adjunctive therapy
of diseases associated with LPS, such as periodontitis,its derivatives inhibit the biological effects of LPS, their
therapeutic applications are still very limited because gram-negative bacterial sepsis, and atherosclerosis.
of the toxicity.
Another known compound having LPS-neutralizing Significance
activity is cathelicidin. Cathelicidin is a novel family of
antibacterial endogenous peptides isolated from the ep- Molecules that can inhibit adhesion molecule expres-
sion in LPS-treated endothelial cells should be usefulithelial tissues and myeloid cells of human and animal
species [49]. About 30 cathelicidin members from vari- as antiinflammatory agents. So, we searched among
microbial secondary metabolites for compounds thatous mammalian species have been identified, and one
of them, hCAP18 (human cationic antibacterial protein could inhibit LPS-stimulated adhesion between hu-
man umbilical vein endothelial cells (HUVEC) and HL-of 18 kDa), was characterized from a human source. Its
carboxyl terminus, called LL-37, which comprises 37 60 cells. As a result, we isolated a novel cyclic depsi-
peptide, which we named heptadepsin, from the wholeamino acid residues, was recently identified in humans,
and LL-37 and its derivatives were reported to possess culture broth of Paenibacillus sp. The addition of hep-
tadepsin prior to LPS stimulation decreased HL-60LPS-neutralizing activity [50]. Originally, cathelicidin
was thought to function in the innate host defense cell-HUVEC adhesion with an IC50 value of 0.92 g/ml.
One of the characteristics of heptadepsin is its lowagainst microbial infections by impairing the mem-
branes of targeted organisms [51]. It had been found toxicity, and heptadepsin did not show any cytotoxicity
or growth inhibition toward HUVEC, even at 30 g/ml.that cathelicidin and its derivatives could block LPS
signal transduction and reduce the mortality associated It also inhibited the cellular adhesion induced by lipid
A, the active component of LPS. However, heptadep-with endotoxemia in the murine model [52]. Recently,
the mechanism by which the cathelicidin family blocks sin did not inhibit HL-60 cell-HUVEC adhesion when
HUVEC were activated by TNF- or IL-1. Interest-the biological activities of LPS was elucidated: they pos-
sess both LPS- and CD14 binding activities and block ingly, heptadepsin was found to interact with lipid A
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1-BuOH. The combined 1-BuOH layers were concentrated in vacuoor LPS directly. Binding of heptadepsin to lipid A was
to give a brown residue (4.67 g). The residue was purified by columnclearly demonstrated by the surface plasmon reso-
chromatography on silicagel 60 (Merck, Darmstadt, Germany) pre-nance (SPR) analyses. We set up the assay system for
packed with 1-BuOH. The active fraction was eluted with a mixture
binding of LPS and the ligand, in which the ligand of 1-BuOH, MeOH, H2O (7:1:1, 1 liter), and concentrated in vacuo
bound to high molecular weight LPS can be removed to give a yellow powder (212 mg). This yellow powder was dissolved
in MeOH and chromatographed on Sephadex LH-20 (100 ml) withby filtration. Heptadepsin was shown to bind to LPS
MeOH (200 ml). After concentration of the active fractions in vacuoin this assay system. These results strongly suggested
to dryness, the residue (18.4 mg) was dissolved in MeOH and rechro-that heptadepsin interacted with LPS directly to inhibit
matographed on Sephadex LH-20 (100 ml) with MeOH (200 ml).the LPS activity. Thus, heptadepsin, a novel naturally
The active fraction was concentrated in vacuo to yield 13.1 mg of
occurring cyclic heptadepsipeptide, was shown to be heptadepsin as a pure white powder.
a new selective inhibitor of LPS-induced signal trans-
duction, acting by direct interaction with LPS. Because Acid Hydrolysis and Determination of the Chirality
of Amino Acidsthe molecular weight of heptadepsin is lower than that
Pure heptadepsin (2.6 mg) was hydrolyzed with 6 N HCl (1 ml) in aof other known LPS-neutralizing agents, and because
sealed tube at 105C for 17 hr. The hydrolyzate was diluted withof its minimal cytotoxicity, heptadepsin may have ther-
H2O (2 ml) and washed with diethyl ether (3 ml) and EtOAc (3 ml).apeutic potential for the treatment of LPS-triggered Evaporation of the aqueous layer gave a residue (1.1 mg) containing
syndromes, such as periodontitis and gram-negative several ninhydrin-positive compounds detected following thin-layer
bacterial sepsis. chromatography (TLC) or high-voltage paper electrophoresis
(HVPE): TLC Rf 0.45, 0.40, 0.28, and 0.22; HVPE Rm 1.0, 0.90–0.85,
0.80. Four known amino acids, isoleucine (TLC Rf 0.45, HVPE RmExperimental Procedures
1.0), valine (Rf 0.40, Rm 0.89), alanine (Rf 0.28, Rm 0.10), and serine
(Rf 0.22, Rm 0.88) were isolated by preparative TLC. Furthermore,Materials
HUVEC were purchased from Cell Systems (Lake Kirkland, WA). HL- aspartic acid (Rf 0.34, Rm 0.78), which had come from an asparagine
residue in heptadepsin, was obtained by preparative HVPE. TLC60 cells were obtained from the Japanese Collection of Research
Bioresources. The mouse pro B cell line Ba/F3 stably expressing was performed on a silica gel plate (Merk Art. 5626) developed
with PrOH/H2O (7:3) and stained with ninhydrin spray (Wako Puremouse TLR4, mouse MD-2, mouse CD14, and p55IgLuc, an NF-
B-dependent luciferase reporter construct, were prepared as de- Chemical). HVPE was carried out with a CAMAG HVE system at
3300 V for 15 min, with HCOOH/CH3COOH/H2O (25:75:900, pH 1.8)scribed previously [57]. LPS (Escherichia coli Serotype 055:B5), lipid
A (1, 4-diphosphoryl form, Escherichia coli F-583), taxol (Paclitaxel; used as the electrolyte solution. The paper was stained with ninhy-
drin reagent, and the relative mobility (Rm) with respect to alaninefrom Taxus brevifolia), BSA, and LTA (Staphylococcus aureus) were
purchased from Sigma Chemical Co. (St. Louis, MO). TNF- was was calculated. Chirality of amino acids was determined with a
chiral HPTLC plate (Merk, HPTLC plate CHIR Art. 14101) developedpurchased from Genzyme-Techne (Cambridge, MA), and IL-1 from
Pepro Tech EC Ltd. (London, UK). Polyclonal antibodies against with MeCN/MeOH/H2O (4:1:1), and the Rf value was compared with
that of the authentic D- or L-amino acid. L-Isoleucine (authentic D,ICAM-1 and VCAM-1 came from Santa Cruz Biotechnology (Santa
Cruz, CA). Alexa Fluor 488-conjugated LPS (Escherichia coli Sero- Rf 0.48; L, 0.61), D-valine (authentic D, Rf 0.48; L, 0.58), D-alanine
(authentic D, Rf 0.42; L, 0.49), L-serine (authentic D, Rf 0.47; L, 0.51),type 055:B5) was purchased from Molecular Plobes (Eugene OR).
HPA biosensor chip was obtained from BIAcore AB (Uppsala, and D-aspartic acid (authentic D, Rf 0.49; L, 0.54) were identified.
Sweden).
Cell Adhesion Assay
HUVEC were seeded at 4
 104 cells/well in 48-well collagen-coatedCell Culture
HUVEC were cultured on type I collagen-coated dishes (Costar, plates (Costar) and cultured overnight at 37C in 5% CO2. The cells
were preincubated with several concentrations of heptadepsin forActon, MA) in MCDB-131 medium (Sigma) supplemented with 10%
heat-inactivated fetal bovine serum (FBS; JRH Biosciences, Lenexa, 2 hr and then treated with the stimulant (1 g/ml LPS, 1 g/ml lipid
A, 10 ng/ml TNF-, or 10 ng/ml IL-1) for 4 hr. Then, the mediumKS) and 10 ng/ml basic fibroblast growth factor (bFGF; Pepro Tech
EC Ltd.). HL-60 cells, THP-1 cells, and Jurkat cells were cultured in was removed, and the wells were washed with phosphate buffered
saline (PBS) twice. Next, leukemic cells (HL-60, THP-1, Jurkat) wereRPMI1640 (Nissui, Tokyo, Japan) supplemented with 10% heat-
inactivated FBS, 100 g/ml kanamycin, 100 units/ml penicillin G, added at 6 
 104 cells/well to the treated HUVEC monolayers. After
1 hr, nonadhering leukemic cells were removed by three washes30 g/ml L-glutamine, and 2.25 g/l NaHCO3. Ba/F3 cells expressing
TLR4-MD-2 and CD14 were cultured in RPMI1640 supplemented with PBS. Then, the number of adherent cells in 1 microscopic field
was counted.with 10% heat-inactivated FBS, 100 g/ml kanamycin, 100 units/ml
penicillin G, 30 g/ml L-glutamine, 2.25 g/liter NaHCO3, 100 M
2-mercaptoethanol, and IL-3, as described previously [57]. Cell Viability and Growth
HUVEC were seeded at 1.6 
 105 cells/well in 24-well collagen-
coated plates (Costar) and cultured overnight. Then, heptadepsinFermentation
A slant culture of Paenibacillus sp. BML771-113F9 was inoculated was added to the cells for 24 hr, and the cell viability was determined
after staining the cells with trypan blue. For the cell growth assay,into a 500 ml Erlenmeyer flask containing 110 ml of a seed medium
composed of 2.5% lactose (Kanto Chemical Co., Tokyo, Japan), HUVEC were seeded at 2
 103 cells/well in 96-well collagen-coated
plates (Costar) and cultured overnight. Then, heptadepsin was7.5% polypeptone (Wako Pure Chemical, Tokyo, Japan), 0.5% meat
extract (Kyokuto, Tokyo, Japan), 0.5% yeast extract (Wako Pure added, and incubation was continued for 72 hr. Cell proliferation
was measured by using the MTT assay.Chemical), 0.2% NaCl, 0.05% MgSO4·7H2O, 0.05% K2HPO4, and
0.2% CaCO3, adjusted to pH 7.4 before sterilization. The inoculated
medium was incubated at 27C for 1 day on a rotary shaker. The Western Blotting Analysis
seed culture (2.2 ml) was then inoculated into a 500 ml Erlenmeyer HUVEC (8 
 105 cells) were treated with LPS for the designed peri-
flask containing 110 ml of the same medium, and incubated at 27C ods. Then, the cells were scraped off and suspended in lysis buffer
for 4 days on a rotary shaker at 180 rpm. (20 mM Tris [pH 8.0], 150 mM NaCl, 2 mM EDTA, 100 mM NaF, 400
M Na3VO4, 1% NP-40, 1 g/ml leupeptin, 1 g/ml antipain, and
1 mM PMSF). The supernatants were combined with loading bufferIsolation and Purification
After the culture period, the whole broth of Paenibacillus sp. (150 mM Tris, 30% glycerol, 3% bromophenol blue, 3% SDS, 15%
2-mercaptoethanol) and electrophoresed in 9% polyacrylamideBML771-113F9 (1 liter, pH 6.4) was washed with an equal volume
of CHCl3 and then extracted three times with an equal volume of gels. The gels were electrophoretically transferred to PVDF mem-
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branes (Amersham Biosciences, Piscataway, NJ) at 4C for 3 hr. Evaluation of the Interaction of Heptadepsin with LPS
Heptadepsin (10 g) was dissolved in 100 l PBS along with 100The membranes were then blocked with 5% skim milk and incubated
with anti-ICAM-1 or anti-VCAM-1 antibody in TBS buffer (20 mM g of LPS, BSA, or LTA and then incubated for 1 hr at 37C. Thereaf-
ter, the mixed solution was put into a centrifugal filter device (Micro-Tris-HCl [pH 7.6] and 137 mM NaCl) at room temperature for 1 hr.
The blotted membranes were next washed six times with 0.2% con YM-3; Millopore Co., Bedford, MA) having a nominal molecular
weight limit (NMWL) of 3,000 daltons, and centrifuged at 14,000
 g.Tween 20 in TN buffer (50 mM Tris-HCl [pH 7.5] and 137 mM NaCl)
and incubated with horseradish-peroxidase-conjugated anti-rabbit Finally, we collected the filtrate and examined its inhibitory activity
toward the HL-60 cell adhesion to LPS-stimulated HUVEC.IgG (Amersham Biosciences) for 1 hr. Immunoreactive proteins were
visualized with the ECL chemiluminescence system (Perkin Elmer
Life Sciences, Boston, MA), and exposed to Fuji Medical X-ray film Supplemental Data
HR-H (Fuji Photo Film, Tokyo, Japan). Supplemental Data, consisting of two tables for the physico-chemi-
cal properties and the NMR data, are available at http://www.
chembiol.com/cgi/content/full/11/8/1059/DC1.
Fluorescence Microscopic Analysis
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